Skip to main content

Table 2 Univariate analysis of association between liver stiffness measurement (LSM) and other variables

From: Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate

  Beta 95% Confidentialinterval P-value
Demographic variables    
Age, years - 0.145 - 0.054, 0.008 0.140
Body mass index, kg/m2 0.134 - 0.041, 0.227 0.173
Disease duration, weeks 0.090 - 0.001, 0.004 0.362
Laboratory variables    
C-reactive protein, mg/L 0.051 - 0.019, 0.032 0.608
Erythrocyte sedimentation rate, mm/hr - 0.147 - 0.026, 0.004 0.135
White blood cell, count/mm3 - 0.071 0.000, 0.000 0.473
Hemoglobin, g/dL 0.050 - 0.232, 0.391 0.612
Platelet count, × 1,000/mm3 - 0.044 - 0.007, 0.004 0.654
Prothrombin time, INR - 0.056 - 6.729, 3.738 0.572
Glucose, mg/dL 0.001 - 0.034, 0.034 0.995
Blood urea nitrogen, mg/dL - 0.045 - 0.085, 0.053 0.651
Creatinine, mg/dL - 0.061 - 2.605, 1.358 0.534
Uric acid. mg/dL 0.148 - 0.058, 0.438 0.132
Aspartate aminotransferase, IU/L 0.146 - 0.014, 0.099 0.136
Alanine aminotransferase, IU/L 0.131 - 0.014, 0.071 0.183
Total protein, mg/dL 0.002 - 0.807, 0.822 0.985
Serum albumin, mg/dL 0.089 - 0.645, 1.741 0.364
Total bilirubin, mg/dL - 0.048 - 2.135, 1.299 0.630
Alkaline phosphatase, IU/L - 0.372 - 0.024, 0.017 0.711
Gamma-glutamyltranspeptidase, IU/L 0.249 0.008, 0.058 0.010
Triglyceride, mg/dL - 0.033 - 0.007, 0.005 0.738
High density cholesterol, mg/dL - 0.185 - 0.050, - 0.001 0.059
Low density cholesterol, mg/dL - 0.161 - 0.022, 0.002 0.101
Cumulative dose of medication, mg    
Methotrexate (105 patients) 0.108 0.000, 0.000 0.273
Leflunomide (53 patients) 0.285 0.000, 0.000 0.038
Sulfasalazine (82 patients) 0.031 0.000, 0.000 0.782
Hydroxychloroquine (65 patients) 0.072 0.000, 0.000 0.567
Prednisolone (89 patients) 0.362 0.000, 0.000 < 0.001
Meloxicam (90 patients) - 0.012 0.000, 0.000 0.909
Celecoxib (70 patients) 0.182 0.000, 0.000 0.131
  1. INR, international normalized ratio.